Vaccine immunogenicity assays are needed to assess the safety and efficacy of the candidate vaccine, by measuring humoral and cellular immune responses, in an effort to correlate with immunity.
At Viracor we develop and perform a variety of molecular assays for virus detection, and other assays for characterizing the humoral and cellular immune response, as part of clinical studies for our clients and their vaccine candidates.
- qPCR assays to detect and quantify the presence of the virus in subject samples, as well as discrimination assays to differentiate wild type virus from vaccine strains
- assays for the detection of one or more anti-drug antibodies (ADAs).
- neutralizing antibody (NAb) assays to characterize neutralizing activity of ADAs, due to their potential impact on pharmacokinetics, pharmacodynamics, safety, and efficacy
- CD4/CD8 quantitation, B-cell response, cytokine release, and other activation assays
- TCID50 (50% tissue culture infective dose) assays
Eurofins Viracor BioPharma partners with Moderna, performing essential clinical trial testing for COVID-19 Vaccine (click to read the full article)
And learn about Eurofins Viracor's expertise with Immunogenicity Assay Development, Validation & Transfer, for use in vaccine candidate clinical trials, as detailed in this case study (click below).
View Case Study